[Russian multicenter clinical trials in acute leukemias]

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Acute leukemias represent a significant challenge in hematologic oncology.
• Historically, survival rates for acute leukemias have varied widely, particularly between specialized centers and regional hospitals.
• The need for standardized, effective treatment protocols across diverse healthcare settings is critical.

Purpose of the Study:

• To evaluate the impact of 27 years of Russian cooperative clinical trials on acute leukemia survival rates.
• To assess the effectiveness of integrated minimal residual disease monitoring and novel non-chemotherapeutic agents.
• To analyze the influence of pregnancy on outcomes in acute leukemia patients.

Main Methods:

• Analysis of data from 15 consecutive Russian clinical trials involving over 2500 patients with acute leukemias.
• Comparison of survival outcomes (5-year overall survival) between different leukemia subtypes (AML, ALL, APL) and treatment periods.
• Integration of minimal residual disease monitoring and evaluation of non-chemotherapeutic treatments (arsenic trioxide, all-trans retinoid acid).

Main Results:

• Significant improvements in 5-year overall survival: AML from 20% to 33%, ALL from 38% to 65%, APL from 0% to 95%.
• Development of reproducible clinical recommendations and protocols adopted by regional hospitals.
• Persistent disparities in outcomes between coordinating and regional centers, with higher early death rates in regional settings (18-25% vs 7.5-9.5%).
• Successful integration of minimal residual disease monitoring for guiding allogeneic stem cell transplantation decisions.
• High efficacy and reduced toxicity observed with non-chemotherapeutic agents like arsenic trioxide and all-trans retinoid acid.
• Pregnancy identified as a poor prognostic factor for acute myeloid leukemia but not for acute lymphoblastic leukemia.

Conclusions:

• Cooperative clinical trials have substantially improved acute leukemia survival in Russia.
• Standardized protocols and advanced monitoring techniques enhance treatment efficacy.
• Addressing regional disparities in early death rates is crucial for optimizing hematologic services nationwide.
• Novel therapeutic approaches offer improved outcomes with better toxicity profiles.
• Pregnancy outcomes differ significantly between AML and ALL, necessitating tailored management strategies.